Comparison of (+)-11C-McN5652 and 11C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions

The brain serotonin (5-HT) system has been implicated in several neuropsychiatric conditions, including major depression, anxiety, obsessive compulsive disorder, and schizophrenia. Because of the perceived importance of the brain 5-HT system in these diseases, as well as a variety of normal brain functions (e.g., appetite, sleep), there has been considerable interest in developing neuroimaging techniques that permit assessment of 5-HT neurons in the living human brain. To this end, several research teams have developed and evaluated various SPECT and PET radiotracers for measurements of various components of the brain 5-HT system (1-6). With regard to PET, a series of radioligands showing high binding to the 5-HT transporter (SERT) in vitro have been evaluated, but most have been found to have insufficient specificity or selectivity for the SERT in vivo (7). To date, one of the more promising PET SERT radioligands identified is trans-1,2,3,5,6,10-β-hexahydro-6-[4-(methylthio)phenyl[pyrrolo-[2,1-a]isoquinoline ((+)-11C-McN5652). (+)-11C-McN5652 binds selectively to the SERT, and its regional distribution of binding in humans correlates well with the known distribution of the SERT in human brain (8-10). In addition, studies in baboons and humans exposed to the brain 5-HT neurotoxin, (±)-3,4-methylenedioxymethamphetamine (MDMA), show significant reductions in (+)-11C-McN5652 binding (11-13). However, usefulness of (+)-11C-McN5652 may be limited by its nonspecific binding and slow release from specific binding sites (14,15). There have been recent reports that an alternative SERT radioligand,3-11C-amino-4-(2-dimethylaminomethylphenylsulfanyl)benzonitrile (11C-DASB), holds promise for use as a SERT PET ligand (16,17). Preclinical studies indicate that, like (+)-11C-McN5652, 11C-DASB has high affinity and selectivity for the SERT in vitro and that, in vivo, it shows saturable and selective binding to the SERT in rodents. Also, damage of 5-HT axon terminals with the neurotoxin p-chloroamphetamine is associated with significant reductions in 11C-DASB binding in vivo in rodents, and low concentrations of radioactive metabolites in rat brain relative to the parent compound (17) suggest that this radioligand holds significant potential for use in evaluating the status of the brain SERT in humans. Notably, initial PET studies in humans (18) indicate that 11C-DASB has highly suitable characteristics for evaluating the status of the SERT in clinical settings and that 11C-DASB can successfully detect SERT occupancy by paroxetine and citalopram (19). The purpose of this study was to compare (+)-11C-McN5652 and 11C-DASB as PET ligands of the SERT in nonhuman primates. In particular, we sought to (a) compare binding characteristics of both radioligands to the SERT in a saline-treated baboon (normal SERT density), (b) compare the ability of the 2 radioligands to detect reductions in SERT density induced by the selective 5-HT neurotoxin MDMA, (c) evaluate the capability of both ligands to detect reduced SERT availability after pretreatment with paroxetine, and (d) determine how binding parameters of the 2 radioligands correlate with direct measures of brain 5-HT axonal markers measured ex vivo.

[1]  Marc Laruelle,et al.  Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites , 1988, Biological Psychiatry.

[2]  M Slifstein,et al.  In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Simon M. Ametamey,et al.  Evaluation of Serotonergic Transporters using PET and [11C](+)McN-5652: Assessment of Methods , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  P. Acton,et al.  2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. , 2000, Nuclear medicine and biology.

[5]  G. Ricaurte,et al.  Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. , 1992, The Journal of pharmacology and experimental therapeutics.

[6]  J. Marcusson,et al.  High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue , 1989, Brain Research.

[7]  M Slifstein,et al.  Validation and Reproducibility of Measurement of 5-HT1A Receptor Parameters with [carbonyl-11C]WAY-100635 in Humans: Comparison of Arterial and Reference Tissue Input Functions , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  Linda Carpenter,et al.  Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography , 1998, Biological Psychiatry.

[9]  Serotonin, the cerebellum, and ataxia , 1993 .

[10]  O Muzik,et al.  Analysis of [C-11]Alpha-Methyl-Tryptophan Kinetics for the Estimation of Serotonin Synthesis Rate In Vivo , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  Russ Rew,et al.  NetCDF: an interface for scientific data access , 1990, IEEE Computer Graphics and Applications.

[12]  Z. Szabo,et al.  In vivo detection of short‐ and long‐term MDMA neurotoxicity—a positron emission tomography study in the living baboon brain , 1998, Synapse.

[13]  R. Dannals,et al.  Synthesis of a radiotracer for studying serotonin uptake sites with positron emission tomography : [11C]McN-5652-Z , 1992 .

[14]  Alan A. Wilson,et al.  Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB , 2000, European Journal of Nuclear Medicine.

[15]  D. Wong,et al.  Column-switching HPLC for the analysis of plasma in PET imaging studies. , 2000, Nuclear medicine and biology.

[16]  Alan A. Wilson,et al.  Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. , 2001, The American journal of psychiatry.

[17]  J. Mazziotta,et al.  Rapid Automated Algorithm for Aligning and Reslicing PET Images , 1992, Journal of computer assisted tomography.

[18]  D. Marquardt An Algorithm for Least-Squares Estimation of Nonlinear Parameters , 1963 .

[19]  Zsolt Szabo,et al.  Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652 , 1995, Synapse.

[20]  J. Mazziotta,et al.  MRI‐PET Registration with Automated Algorithm , 1993, Journal of computer assisted tomography.

[21]  D. Kupfer,et al.  Serotonin in Aging, Late-Life Depression, and Alzheimer's Disease: The Emerging Role of Functional Imaging , 1998, Neuropsychopharmacology.

[22]  M. Kraut,et al.  Kinetic Analysis of [11C]McN5652: A Serotonin Transporter Radioligand , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  B. Bailey Tables of the Bonferroni t Statistic , 1977 .

[24]  P. Brust,et al.  Radioligands for the study of the 5-HT transporter in vivo. , 1999, IDrugs : the investigational drugs journal.

[25]  J. Palacios,et al.  Autoradiography of antidepressant binding sites in the human brain: localization using [3h]imipramine and [3h]paroxetine , 1988, Neuroscience.

[26]  G. Ricaurte,et al.  Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[27]  H N Wagner,et al.  Positron Emission Tomography of 5-HT Transporter Sites in the Baboon Brain with [11C]McN5652 , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  Z. Szabo,et al.  Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). , 2000, Toxicology letters.